Next-generation sequencing provides an opportunity to offer personalised healthcare to cancer patients. However, it is challenging to interpret sequencing data and translate it into a treatment strategy. Molecular tumour boards, composed of clinical oncologists and pathologists alongside other specialists, are required to evaluate the data and identify treatment options.
In this session, our speakers will discuss the application of molecular tumour boards in treating patients with breast cancer. They will discuss the opportunities to provide personalised healthcare in the early and advanced disease settings and the challenges that may arise. We will also hear about the role of germline genetics to personalise treatment for breast cancer.
By the end of the session attendees will understand how molecular tumour boards can be used to inform the treatment of breast cancer patients, the opportunities to improve outcomes for these patients and the challenges that still exist in the use of molecular tumour boards.
- Mr Stuart McIntosh – Queen’s University Belfast and Chair of the NCRI Breast Group, UK
- Professor Jean Abraham – Cambridge University Hospitals NHS Foundation Trust, UK
- Dr Richard Baird – Cambridge University Hospitals NHS Foundation Trust, UK
- Dr Ellen Copson – University of Southampton, UK
2 category 1 (external) CPD credits for this session have been approved by the Federation of the Royal Colleges of Physicians. Delegates requiring a CPD certificate can add this during the registration process for a charge of £15. CPD Certificates will be sent automatically up to 10 days after the event date.
Who should attend?
Anyone interested or working in breast cancer research, treatment and care, including medical/clinical oncologists, surgeons, early career researchers, nurses, allied health professionals, PhD and undergraduate students.
Anyone interested in the use of molecular analysis and personalised healthcare in cancer treatment, including clinical geneticists, pathologists, bioinformaticians, scientists and bioethicists.
Others involved in breast cancer research including, patients and carers and research managers/funders.